Christopher J. Logothetis, MD of MD Anderson Cancer Center discusses the impact of cost with the introduction of abiraterone as standard of care for patients with prostate cancer. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.
If abiraterone becomes the standard care, will there be cost implications?
